How the genetics of lung cancer may overlap with COPD

Respirology

Volumn 16, Issue 7, 2011, Pages 1047-1055

  Young, Robert P ^a   Hopkins, Raewyn J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

chronic obstructive pulmonary disease; genetics; lung cancer; tobacco

Indexed keywords

ADAM PROTEIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; NICOTINIC RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY REMODELING; APOPTOSIS; BRONCHUS MUCOSA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; INTRACELLULAR SIGNALING; LUNG CANCER; LUNG CARCINOGENESIS; LUNG FUNCTION; MALIGNANT TRANSFORMATION; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING; SPIROMETRY; SYSTEMATIC REVIEW;

AIRWAY REMODELING; EPITHELIAL-MESENCHYMAL TRANSITION; FORCED EXPIRATORY VOLUME; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; RISK FACTORS; SMOKING;

EID: 80053300494     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02019.x     Document Type: Review

References (93)

1. Broderick P, Wang Y, Vijayakarishnan V, et al,. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009; 69: 6633-41.
2. Molfino NA,. Genetics of COPD. Chest 2004; 125: 1929-40. (Pubitemid 38648430)
3. Witschi H,. A short history of lung cancer. Toxicol Sci. 2001; 64: 4-6. (Pubitemid 33062181)
4. National Cancer Institute. SEER Statistics and Facts. [Accessed 25 July 2011.] Available from URL
5. Buist AS, McBurnie MA, Vollmer WM, et al,. International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet 2007; 370: 741-50. (Pubitemid 47321907)
6. Minino AM, Xu J, Kochanek KD,. Deaths: Preliminary Data for 2008. National Centre for Health statistics, Hyattsville, MD, 2010; 59 (2). National Vital Statistics Reports. S010.
7. Mattson ME, Pollack ES, Cullen JW,. What are the odds that smoking will kill you? Am. J. Public Health 1987; 77: 425-31. (Pubitemid 17044055)
8. Kohansal R, Martinez-Camblor P, Agusti A, et al,. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am. J. Respir. Crit. Care Med. 2009; 180: 3-10.
9. Løkke A, Lange P, Scharling H, et al,. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-9. (Pubitemid 44787161)
10. Lichtenstein P, Holm NV, Verkasalo PK, et al,. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark and Finland. N. Eng. J. Med. 2000; 343: 78-85. (Pubitemid 30451850)
11. Chen Y,. Genetic epidemiology of pulmonary function. Thorax 1999; 54: 818-24. (Pubitemid 29401545)
12. Burrows B, Knudson RJ, Cline MG, et al,. Qualitative relationships between cigarette smoking and ventilatory function. Am. Rev. Respir. Dis. 1977; 115: 195-205. (Pubitemid 8036155)
13. Cohen BH, Diamond EL, Graves CVG, et al,. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 1977; September: 523-6. (Pubitemid 8186302)
14. Dockery DW, Speizer FE, Ferris BG, et al,. Cumulative and reversible effects of lifetime smoking on simple tests of lung function in adults. Am. Rev. Respir. Dis. 1988; 137: 286-92. (Pubitemid 18050173)
15. Tockman MS, Anthonisen NR, Wright NC, et al,. Airways obstruction and the risk of lung cancer. Ann. Intern. Med. 1987; 106: 512-18. (Pubitemid 17095034)
16. Mannino DM, Aguayo SM, Petty TL, et al,. Low lung function and incident lung cancer in the United States: data from the first NHANES follow-up. Arch. Intern. Med. 2003; 163: 1475-80. (Pubitemid 36758921)
17. Young RP, Hopkins RJ, Christmas T, et al,. COPD prevalence is increased in lung cancer independence of age, gender and smoking history. Eur. Respir. J. 2009; 34: 380-6.
18. Young RP, Hopkins R, Eaton TE,. FEV1: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 2007; 30: 616-22. (Pubitemid 351194819)
19. Thorgeirsson TE, Geller F, Sulem P, et al,. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452: 638-42. (Pubitemid 351483366)
20. Hung RJ, McKay JD, Gaborieau V, et al,. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-7. (Pubitemid 351483367)
21. Amos CI, Wu X, Broderick P, et al,. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 2008; 40: 616-22. (Pubitemid 351601203)
22. Young RP, Hopkins R, Black PN, et al,. Functional variants of anti-oxidant genes in smokers with COPD and in those with normal lung function. Thorax 2006; 30: 394-9. (Pubitemid 43723321)
23. de Torres J, Bastarrika G, Wisnivesky JP, et al,. Assessing the relationship between lung cancer risk and emphysema detected on low dose CT of the chest. Chest 2007; 132: 1932-8.
24. Wilson DO, Weissfeld JL, Balkan A, et al,. Association of radiographic emphysema and airflow obstruction with lung cancer. Am. J. Respir. Crit. Care Med. 2008; 178: 738-44.
25. Calabra E, Randi G, La Vecchia C, et al,. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur. Respir. J. 2010; 35: 146-51.
26. Hill K, Goldstein RS, Guyatt GH, et al,. Prevalence and under-diagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010; 182: 673-8.
27. Frayling TM,. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat. Rev. Genet. 2007; 8: 657-62. (Pubitemid 47281993)
28. Petty TL,. Are COPD and lung cancer two manifestations of the same disease? Chest 2005; 128: 1895-7. (Pubitemid 41507515)
29. Punturieri A, Szabo E, Croxton TL, et al,. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. JNCI 2009; 101: 554-9.
30. Young RP, Hopkins RJ, Hay BA, et al,. Lung cancer gene associated with COPD: triple whammy or possible confounding effect? Eur. Respir. J. 2008; 32: 1158-64.
31. Young RP, Whittington CF, Hopkins RJ, et al,. Chromosome 4q31 locus in COPD also associated with lung cancer. Eur. Respir. J. 2010; 36: 1375-82.
32. Young RP, Hopkins RJ, Hay BA, et al,. FAM13A locus in COPD independently associated with lung cancer-evidence of a molecular genetic link between COPD and lung cancer. Appl. Clin. Genet. 2011; 4: 1-13.
33. Castaldi PJ, Cho MH, Cohn M, et al,. The COPD genetic association compendium: a comprehensive online data base of COPD genetic associations. Hum. Mol. Genet. 2009; 19: 526-34.
34. Smolonska J, Wijmenga C, Postma DS, et al,. Meta-analyses on suspected chronic obstructive pulmonary disease genes-a summary of 20 years research. Am. J. Respir. Crit. Care Med. 2009; 180: 618-31.
35. Carlsten C, Sagoo GS, Frodsham AJ, et al,. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature based systematic HuGE review and meta-analysis. Am. J. Epidemiol. 2008; 167: 759-74. (Pubitemid 351451750)
36. Hung RJ, Christiani DC, Risch A, et al,. International lung cancer consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 3081-9.
37. Wilk J, Walter R, Laramie J, et al,. Framingham heart study genome-wide association: results for pulmonary function measures. BMC Med. Genet. 2007; 8 (S1): S8.
38. Wilk JB, Chen T, Gottlieb DJ, et al,. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet. 2009; 5: e1000429.
39. Repapi E, Sayers I, Wain LV, et al,. Genome-wide association study identifies five loci associated with lung function. Nat. Genet. 2009; 42: 36-44.
40. Hancock DB, Eijgelsheim M, Wilk JB, et al,. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat. Genet. 2009; 42: 45-52.
41. Pillai SG, Ge D, Zhu G, et al,. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009; 5: e1000421.
42. Cho MH, Boutaoui N, Klanderman BJ, et al,. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat. Genet. 2010; 42: 200-2.
43. Young RP, Hopkins RJ, Whittington CF, et al,. Individual and cumulative effects of GWAS susceptibility loci in lung cancer: associations after genotyping for COPD. PLoS ONE. 2011; 6: e16476.
44. Gwilt CR, Donnelly LE, Rogers DF,. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol. Ther. 2007; 115: 208-22. (Pubitemid 47042914)
45. Watkins DN, Berman DM, Burkholder SG, et al,. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003; 422: 313-17. (Pubitemid 36378358)
46. Kandpal RP,. Rho GTPase Activating Proteins in Cancer Phenotypes. Curr. Protein Pept. Sci. 2006; 7: 355-65.
47. Richens TR, Linderman DJ, Horstmann SA, et al,. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of Rho A. Am. J. Respir. Crit. Care Med. 2009; 179: 1011-21.
48. Asnaghi L, Vass WC, Quadri R, et al,. E-Cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of GTPases. Oncogene 2010; 29: 2760-71.
49. Young RP, Hopkins R, Eaton TE,. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222-32.
50. Young RP, Hopkins RJ,. COPD and lung cancer: are they both airways diseases? Chest 2011 (in press).
51. Yang IA, Relan V, Wright CM, et al,. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin. Ther. Targets 2011; 15: 439-56.
52. Schwartz AG, Ruckdeschel JC,. Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 173: 16-22. (Pubitemid 43069784)
53. Barnes PJ, Celli BR,. Systemic manifestations and co-morbidities of COPD. Eur. Respir. J. 2009; 33: 1165-85.
54. Young RP, Hopkins RJ, Hay BA, et al,. A gene based risk score for lung cancer susceptibility in smokers and ex-smokers. Postgrad. Med. J. 2009; 85: 515-24.
55. Young RP, Hopkins RJ, Hay BA, et al,. Lung cancer susceptibility model based on age, family history and genetic variants. PLoS ONE 2009; 4: e5302.
56. Young RP, Hopkins RJ,. Link between COPD and lung cancer. Respir. Med. 2010; 104: 758-9.
57. Strange C,. COPD and lung cancer: are they both airways diseases? Chest 2010; 138: 1289-90.
58. Potton E, McCaughan F, Janes S,. Chronic obstructive pulmonary disease and lung cancer. Respir Med. 2009; 5: 34-7. COPD Update.
59. Lee G, Walser TC, Dubinett SM,. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr. Opin. Pulm. Med. 2009; 15: 303-7.
60. Brody JS, Spira A,. Chronic obstructive pulmonary disease, inflammation and lung cancer. Proc. Am. Thorac. Soc. 2006; 3: 535-8.
61. Yao HW, Rahman I,. Current concepts on the role of inflammation in COPD and lung cancer. Curr. Opin. Pharmacol. 2009; 9: 375-83.
62. Caramori G, Casolari P, Cavallesco GN, et al,. Mechanisms involved in lung cancer development in COPD. Int. J. Biochem. Cell Biol. 2011; 43: 1030-44.
63. Wang IM, Stepaniants S, Boie Y, et al,. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am. J. Respir. Crit. Care Med. 2008; 177: 402-11. (Pubitemid 351317583)
64. Qu P, Roberts J, Li Y, et al,. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009; 63: 341-7.
65. Houghton AM, Mouded M, Shapiro SD,. Common origins of lung cancer and COPD. Nat. Med. 2008; 14: 1023-4.
66. Caramori G, Adcock IM, Casolari P, et al,. Unbalanced oxidant-induced DNA damage and repair in COPD; a link towards lung cancer. Thorax 2011; 66: 521-7.
67. Chung KF, Adcock IM,. Multifaceted mechanisms in COPD: inflammation, immunity and tissue repair and destruction. Eur. Respir. J. 2008; 31: 1334-55.
68. Cosio MG, Saetta M, Agusti A,. Immunologic Aspects of Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 2009; 360: 2445-54.
69. Borchers MT, Wesselkamper SC, Curull V, et al,. Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease. J. Clin. Invest. 2009; 119: 636-49.
70. Evans SE, Xu Y, Tuvim MJ, et al,. Inducible Innate Resistance of Lung Epithelium to Infection. Annu. Rev. Physiol. 2010; 72: 413-35.
71. Sohal SS, Reid D, Soltani A, et al,. Reticular basement membrane fragmentation and potential mesenchymal transition is exaggerated in the airways of smokers with chronic obstructive pulmonary disease. Respirology 2010; 15: 930-8.
72. Dasari V, Gallup M, Lemjabbar H, et al,. Epithelial-mesenchymal transition in lung cancer: is tobacco the 'smoking gun'? Am. J. Respir. Cell Mol. Biol. 2006; 35: 3-9. (Pubitemid 43993148)
73. Shintani Y, Maeda M, Chaika N, et al,. Collagen 1 promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-β signalling. Am. J. Respir. Cell Mol. Biol. 2008; 38: 95-104.
74. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119: 1420-8.
75. Kissil JL, Walmsley MJ, Hanlon L, et al,. Requirement for Rac1 in a K-ras-induced lung cancer in the Mouse. Cancer Res. 2007; 67: 8089-94. (Pubitemid 47395143)
76. Zondag GCM, Evers EE, ten Klooster JP, et al,. Oncogenic Ras down regulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J. Cell Biol. 2000; 149: 775-82.
77. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, et al,. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir. Med. 2009; 103: 1548-53.
78. Dowlati A, Levitan N, Remick SC,. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J. Lab. Clin. Med. 1999; 134: 405-9. (Pubitemid 29490161)
79. Begany T,. Mounting evidence that IL-6 contributes to lung cancer. Pulm. Rev. 2005; November: 17.
80. Ancrile B, Lim K-H, Counter CM,. Oncogenic Ras-induced secretion of IL-6 is required for tumorigenesis. Mol. Interv. 2008; 8: 22-7.
81. Shi W, Chen F, Cardoso WV,. Mechanisms of lung development-contribution to adult lung disease and relevance to chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2009; 6: 558-63.
82. Arnaud C, Burger F, Steffens S, et al,. Statins reduce interleukin-6 induced C-reactive protein in human hepatocytes: new evidence for direct anti-inflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 1231-6. (Pubitemid 40776614)
83. Walser T, Cui X, Yanagawa J, et al,. Smoking and lung cancer-the role of inflammation. Proc. Am. Thorac. Soc. 2008; 5: 811-15.
84. Patel S, Mason RM, Suzuki J, et al,. Inhibitory effect of statins on renal Epithelial-to-Mesenchymal Transition. Am. J. Nephrol. 2006; 26: 381-7. (Pubitemid 44394157)
85. Young RP, Hopkins RJ, Eaton TE,. Potential benefits of statins on morbidity and mortality in COPD: a review of the evidence. Postgrad. Med. J. 2009; 85: 414-21.
86. Young R, Hopkins R,. Lung function predicts lung cancer. Eur. Respir. J. 2010; 35: 1421-2.
87. Peto R, Darby S, Deo H, et al,. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. Br. Med. J. 2000; 321: 323-9. (Pubitemid 30496873)
88. Spitz MR, Amos CI, D'Amellio A, et al,. Re: discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. JNCI 2009; 24: 1731-2.
89. Young RP, Hopkins RJ, Smith M, et al,. Smoking cessation: the potential role of risk assessment tools as motivational triggers. Postgrad. Med. J. 2010; 86: 26-33.
90. Carpenter MJ, Strange C, Jones Y, et al,. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann. Behav. Med. 2007; 33: 22-8.
91. TM) Motivates Smoking Cessation In Randomly Selected Smokers. Abstract #A65. AACR 2010; 3 (12 Suppl.): A65.
92. Bechtel JJ, Kelley WA, Coons TA, et al,. Lung cancer detection in patients with airflow obstruction identified in a primary care outpatient practice. Chest 2005; 127: 1140-5. (Pubitemid 46224273)
93. IELCAP Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. NEJM 2006; 355: 1763-71.